CR20110585A - Anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-amiloide - Google Patents

Anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-amiloide

Info

Publication number
CR20110585A
CR20110585A CR20110585A CR20110585A CR20110585A CR 20110585 A CR20110585 A CR 20110585A CR 20110585 A CR20110585 A CR 20110585A CR 20110585 A CR20110585 A CR 20110585A CR 20110585 A CR20110585 A CR 20110585A
Authority
CR
Costa Rica
Prior art keywords
protofibrillary
beta
humanized antibodies
antibodies specific
amyloid peptide
Prior art date
Application number
CR20110585A
Other languages
English (en)
Inventor
Nicolas Baurin
Francis Blanche
Béatrice Cameron
Marc Duchesne
Vincent Mikol
Souad Naimi
Laurent Pradier
Yi Shi
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41591699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110585(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CR20110585A publication Critical patent/CR20110585A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-amiloide, así como la utilización de estos anticuerpos en el ámbito de la enfermedad de Alzheimer.
CR20110585A 2009-05-12 2011-11-08 Anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-amiloide CR20110585A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0953133A FR2945538B1 (fr) 2009-05-12 2009-05-12 Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.

Publications (1)

Publication Number Publication Date
CR20110585A true CR20110585A (es) 2011-12-07

Family

ID=41591699

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110585A CR20110585A (es) 2009-05-12 2011-11-08 Anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-amiloide

Country Status (42)

Country Link
US (4) US8614299B2 (es)
EP (3) EP2430049B1 (es)
JP (2) JP2012526541A (es)
KR (1) KR101783058B1 (es)
CN (1) CN102459336B (es)
AR (1) AR076670A1 (es)
AU (1) AU2010247215B2 (es)
BR (1) BRPI1012853B1 (es)
CA (1) CA2761665A1 (es)
CL (1) CL2011002831A1 (es)
CO (1) CO6460745A2 (es)
CR (1) CR20110585A (es)
CY (2) CY1116842T1 (es)
DK (2) DK2977385T3 (es)
EA (1) EA028357B1 (es)
EC (1) ECSP11011452A (es)
ES (2) ES2664409T3 (es)
FR (1) FR2945538B1 (es)
GT (1) GT201100283A (es)
HK (1) HK1167152A1 (es)
HR (3) HRP20150776T1 (es)
HU (1) HUE036737T2 (es)
IL (1) IL216237B (es)
LT (1) LT2977385T (es)
MA (1) MA33350B1 (es)
MX (1) MX2011012060A (es)
MY (1) MY159398A (es)
NI (1) NI201100195A (es)
NZ (1) NZ596540A (es)
PE (1) PE20120906A1 (es)
PL (2) PL2430049T3 (es)
PT (2) PT2430049E (es)
RS (1) RS54122B1 (es)
SG (1) SG176155A1 (es)
SI (2) SI2977385T1 (es)
SV (1) SV2011004058A (es)
TN (1) TN2011000571A1 (es)
TW (2) TWI542360B (es)
UA (1) UA107574C2 (es)
UY (1) UY32633A (es)
WO (1) WO2010130946A1 (es)
ZA (1) ZA201108301B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2207568B1 (en) 2007-11-16 2017-05-31 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
AR085302A1 (es) * 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
JP2013159596A (ja) * 2012-02-08 2013-08-19 Nihon Univ β−アミロイド前駆体タンパク質のマイクロ凝集体に特異的なモノクローナル抗体
JP6463331B2 (ja) 2013-03-15 2019-01-30 イントリンシック ライフサイエンシズ リミテッド ライアビリティ カンパニー 抗ヘプシジン抗体およびその使用
EP4066859A1 (en) 2014-08-08 2022-10-05 Alector LLC Anti-trem2 antibodies and methods of use thereof
EP3197915A4 (en) 2014-09-22 2018-12-19 Intrinsic Lifesciences LLC Humanized anti-hepcidin antibodies and uses thereof
IL254887B2 (en) 2015-04-07 2023-11-01 Alector Llc Anti-sortilin antibodies and methods of using them
CN116063499A (zh) 2015-06-12 2023-05-05 艾利妥 抗cd33抗体及其使用方法
JP7497953B2 (ja) 2015-06-12 2024-06-11 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
JP2018522891A (ja) 2015-07-21 2018-08-16 バイオアークティック アーベー 凝集ペプチドを標的とする外傷性脳損傷の治療方法
CN108137702B (zh) 2015-08-28 2023-01-06 艾利妥 抗siglec-7抗体及其使用方法
CN108738323B (zh) 2015-10-06 2023-05-26 艾利妥 抗trem2抗体及其使用方法
JP7060502B2 (ja) 2015-10-29 2022-04-26 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－９抗体及びその使用方法
EP3423493A2 (en) 2016-03-04 2019-01-09 Alector LLC Anti-trem1 antibodies and methods of use thereof
US11339209B2 (en) 2016-11-14 2022-05-24 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion
EP3354278A1 (en) * 2017-01-31 2018-08-01 Sanofi Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
US11359014B2 (en) 2017-05-16 2022-06-14 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
CR20230170A (es) 2017-08-03 2023-05-31 Alector Llc ANTICUERPOS ANTI-TREM2 Y MÉTODOS PARA UTILIZARLOS (divisional 2019-0485)
WO2019028283A1 (en) 2017-08-03 2019-02-07 Alector Llc ANTI-CD33 ANTIBODIES AND METHODS OF USE
JP7337099B2 (ja) 2018-05-25 2023-09-01 アレクトル エルエルシー 抗ｓｉｒｐａ抗体およびその使用法
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
MA52764A (fr) 2018-06-08 2021-04-28 Alector Llc Anticorps anti-siglec-7 et leurs méthodes d'utilisation
US11396546B2 (en) 2018-07-13 2022-07-26 Alector Llc Anti-Sortilin antibodies and methods of use thereof
MA53328A (fr) 2018-07-27 2021-06-09 Alector Llc Anticorps anti-siglec-5 et leurs procédés d'utilisation
CN113801229A (zh) 2018-08-31 2021-12-17 艾利妥 抗cd33抗体及其使用方法
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
TW202110878A (zh) 2019-05-16 2021-03-16 法商賽諾菲公司 在神經系統中表現抗原結合蛋白
KR20220032568A (ko) 2019-06-25 2022-03-15 길리애드 사이언시즈, 인코포레이티드 Flt3l-fc 융합 단백질 및 사용 방법
CA3151927A1 (en) * 2019-08-20 2021-02-25 The Curators Of The University Of Missouri Amyloid-beta antibodies
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
US20230035072A1 (en) 2019-12-12 2023-02-02 Alector Llc Methods of use of anti-cd33 antibodies
CA3187085A1 (en) 2020-08-25 2022-03-03 Manuel Baca Multi-specific antigen binding molecules targeting hiv and methods of use
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
JP2005500806A (ja) * 2000-09-15 2005-01-13 コーリー ファーマシューティカル ゲーエムベーハー ＣｐＧに基づく免疫アゴニスト／免疫アンタゴニストの高スループットスクリーニングのためのプロセス
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20060024302A1 (en) * 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EP2314317A3 (en) * 2004-07-09 2011-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
US7807165B2 (en) * 2004-07-30 2010-10-05 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
CA2582683A1 (en) * 2004-10-01 2006-04-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel antibodies directed to the mammalian eag1 ion channel protein
CA2589860A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
WO2007108755A1 (en) * 2006-03-22 2007-09-27 Gyros Patent Ab Plex method
EP2325209A3 (en) * 2006-03-23 2011-08-03 BioArtic Neuroscience AB Improved protofibril selective antibodies and the use thereof
PT2099826E (pt) * 2007-01-05 2014-01-09 Univ Zuerich Anticorpo anti-beta-amilóide e suas utilizações
ES2582386T3 (es) * 2007-03-01 2016-09-12 Symphogen A/S Composiciones de anticuerpos recombinantes contra el receptor del factor de crecimiento epidérmico
NZ583605A (en) 2007-08-29 2012-10-26 Sanofi Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2207568B1 (en) * 2007-11-16 2017-05-31 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
MX2010014319A (es) * 2008-07-08 2011-05-19 Geneuro Sa Uso terapeutico de ligando especifico en enfermedades asociadas con msrv.
EP2406290B1 (en) * 2009-03-10 2017-07-05 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
CN105837691B (zh) * 2009-03-10 2021-06-29 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
TWI508976B (zh) * 2009-04-21 2015-11-21 Univ Rockefeller 對β－類澱粉蛋白之基原纖維形式具專一性之抗體

Also Published As

Publication number Publication date
SI2977385T1 (en) 2018-05-31
TW201100102A (en) 2011-01-01
MX2011012060A (es) 2012-04-30
ES2542757T3 (es) 2015-08-11
BRPI1012853B1 (pt) 2021-08-24
ECSP11011452A (es) 2011-12-30
JP2016028591A (ja) 2016-03-03
GT201100283A (es) 2013-11-07
JP6310895B2 (ja) 2018-04-11
EP2430049A1 (fr) 2012-03-21
CL2011002831A1 (es) 2012-05-11
US9382312B2 (en) 2016-07-05
AU2010247215A1 (en) 2011-12-15
RS54122B1 (en) 2015-12-31
ZA201108301B (en) 2013-01-30
TN2011000571A1 (fr) 2013-05-24
SI2430049T1 (sl) 2015-08-31
IL216237A0 (en) 2012-01-31
US20120177639A1 (en) 2012-07-12
HRP20180516T1 (hr) 2018-05-04
EP3050898B1 (fr) 2018-08-15
DK2430049T3 (en) 2015-07-20
DK2977385T3 (en) 2018-04-16
PL2977385T3 (pl) 2018-06-29
HUE036737T2 (hu) 2018-07-30
FR2945538B1 (fr) 2014-12-26
JP2012526541A (ja) 2012-11-01
FR2945538A1 (fr) 2010-11-19
UY32633A (es) 2010-12-31
SV2011004058A (es) 2012-06-06
US20190119365A1 (en) 2019-04-25
EP2977385A1 (fr) 2016-01-27
AU2010247215B2 (en) 2015-08-20
EA201171388A1 (ru) 2012-05-30
CY1116842T1 (el) 2017-03-15
HRP20181985T1 (hr) 2019-01-25
PT2977385T (pt) 2018-04-03
CA2761665A1 (fr) 2010-11-18
TWI542360B (zh) 2016-07-21
US20160368977A1 (en) 2016-12-22
PL2430049T3 (pl) 2015-09-30
PE20120906A1 (es) 2012-08-08
KR101783058B1 (ko) 2017-09-28
TW201641690A (zh) 2016-12-01
BRPI1012853A2 (pt) 2018-06-19
HK1167152A1 (en) 2012-11-23
US10112991B2 (en) 2018-10-30
WO2010130946A1 (fr) 2010-11-18
PT2430049E (pt) 2015-09-01
TWI583791B (zh) 2017-05-21
LT2977385T (lt) 2018-04-10
US8614299B2 (en) 2013-12-24
CN102459336B (zh) 2016-04-20
UA107574C2 (ru) 2015-01-26
CY1120413T1 (el) 2019-07-10
CO6460745A2 (es) 2012-06-15
MA33350B1 (fr) 2012-06-01
HRP20150776T1 (hr) 2015-08-28
US20140105890A1 (en) 2014-04-17
AR076670A1 (es) 2011-06-29
MY159398A (en) 2016-12-30
EP2430049B1 (fr) 2015-04-15
IL216237B (en) 2018-05-31
EP2977385B1 (fr) 2017-12-27
CN102459336A (zh) 2012-05-16
ES2664409T3 (es) 2018-04-19
SG176155A1 (en) 2011-12-29
NZ596540A (en) 2013-05-31
KR20120096950A (ko) 2012-08-31
NI201100195A (es) 2012-02-01
EA028357B1 (ru) 2017-11-30
EP3050898A1 (fr) 2016-08-03

Similar Documents

Publication Publication Date Title
CR20110585A (es) Anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-amiloide
DOP2017000046A (es) Anticuerpos anti tigit
BR112012029917A2 (pt) composições de nanotransportador com adjuvante desacoplado
EA201590173A1 (ru) Иммуноконъюгаты, содержащие антитела к cd22
EA201101530A1 (ru) ИММУНОНАНОТЕРАПИЯ, ОБЕСПЕЧИВАЮЩАЯ Th1-СМЕЩЕННЫЙ ОТВЕТ
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
UA111818C2 (uk) Антитіло проти csf-1r
HN2011002809A (es) Compuestos de vinil indazolilo
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
ECSP11011541A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
UY34486A (es) Anticuerpos dirigidos al receptor del factor de crecimiento epidérmico 3 (her3) dirigidos contra el dominio ii del her3
MX357656B (es) Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.
MX2013008699A (es) Compuestos para reducir la produccion de beta-amiloide.
CA2851761C (en) Method of diagnosis, prognostic or treatment of neurodegenerative diseases
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
EA201401045A1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
CY1117740T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
AR120118A2 (es) Anticuerpos anti tigit
BR112012009497A2 (pt) agonistas peptídicos de glp-2
UY3859U (es) Motocicleta
IN2012DN03074A (es)
TH108693B (th) เตียง
TH108688B (th) เตียง
PL401425A1 (pl) Odwar lawendowy o właściwościach antyrodnikowych